Previous Article | Next Article 
Journal of Clinical Microbiology, December 2001, p. 4387-4389, Vol. 39, No. 12
CAST Laboratories and Department of
Pathology, University of Iowa College of Medicine, Iowa
City,1 and The JONES Group, North
Liberty,3 Iowa, and AB BIODISK, Solna,
Sweden2
Received 8 June 2001/Returned for modification 17 August
2001/Accepted 21 September 2001
The performance of the Etest for testing the susceptibilities to
caspofungin (MK-0991) of 726 isolates of Candida spp. was assessed against the National Committee for Clinical Laboratory Standards (NCCLS) microdilution broth method. The NCCLS method employed
RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35°C. MICs were determined by Etest for all 726 isolates with
RPMI agar containing 2% glucose (RPG) and were read after incubation
for 48 h at 35°C. The Candida isolates included
Candida albicans (n = 486), Candida
glabrata (n = 96), Candida
tropicalis (n = 51), Candida
parapsilosis (n = 47), Candida
krusei (n = 11), Candida lusitaniae
(n = 2), and Candida guilliermondii
(n = 33). In addition, a subset of 314 isolates were
also tested by Etest using Casitone agar (CAS) and antibiotic medium 3 agar (AM3). The Etest results obtained using RPG correlated well with
reference MICs. Overall agreement was 94% with RPG, 82% with CAS, and
79% with AM3. When RPG was used, agreement ranged from 79% for
C. parapsilosis to 100% for C. krusei,
C. lusitaniae, and C. guilliermondii. When CAS
was used, agreement ranged from 0% for C. lusitaniae to
100% for C. glabrata. With AM3, agreement ranged from 0%
for C. lusitaniae to 100% for C. guilliermondii. All three media supported growth of each of the
Candida species. Etest results were easy to read, with
sharp zones of inhibition. In most instances (75%) where a discrepancy
was observed between the Etest and the reference method, the Etest MIC
was lower. The Etest method using RPG appears to be useful for
determining caspofungin susceptibilities of Candida species.
The standardization of broth
dilution methods for performing antifungal susceptibility testing of
yeasts has set the stage for the development of alternative testing
methods that may be easier to perform in the clinical laboratory
(1, 4-7, 10, 12, 14, 15). These include both broth- and
agar-based methods. Agar-based methods for antimicrobial susceptibility
testing are widely used in microbiology laboratories and include disk
diffusion testing, agar dilution, and the Etest stable-gradient method
(8). In many instances agar-based methods may allow for
enhanced detection of antimicrobial resistance (7, 9, 14, 15,
23). Although agar-based methods are not widely used for
performing antifungal susceptibility testing, recent studies have shown
that both disk diffusion testing and the Etest may be useful for
testing yeasts and moulds (1, 4-7, 9, 10, 14-17,
19-21).
Among the newer antifungal agents, the water-soluble glucan synthesis
inhibitor caspofungin (MK-0991; Merck Research Laboratories, Rahway,
N.J.), has potent fungicidal activity against pathogenic yeasts
including most species of Candida (3, 10, 11, 13, 22). This agent has been tested extensively in broth but has not
been widely evaluated using an agar-based testing method. Recently,
Lozano-Chiu et al. (10) reported a simple disk diffusion method for determining the in vitro susceptibility testing of caspofungin against Candida spp. They demonstrated a good
correlation between zone diameter and MICs determined using the
National Committee for Clinical Laboratory Standards (NCCLS)
recommended broth microdilution method. Although simple to perform, the
disk test provides qualitative data only. Thus, the development of a
quantitative agar-based test such as the Etest may be desirable.
The Etest has proven useful for testing amphotericin B and the azoles
against a variety of fungal pathogens (4-7, 9, 16, 17, 19-21,
23). The choice of agar medium may be important in optimizing
the performance of Etest for some antifungal agents (6, 9, 16,
17, 19, 20, 23). Thus far, the Etest has not been applied to the
testing of caspofungin or other glucan synthesis inhibitors against
Candida. In the present study, we evaluated the Etest for
caspofungin, using RPMI, Casitone, and antibiotic medium 3 agars, in
comparison to the NCCLS reference microdilution method for testing 726 clinical isolates of Candida spp.
Test organisms.
A total of 726 clinical isolates of
Candida species were selected for testing. The collection
included 486 Candida albicans, 96 Candida
glabrata, 51 Candida tropicalis, 47 Candida
parapsilosis, 33 Candida guilliermondii, 11 Candida krusei, and 2 Candida lusitaniae isolates. The members of this collection were all recent clinical isolates from geographically diverse medical centers in North and Latin
America. The majority were isolated from blood or normally sterile body
fluids (18). The isolates were identified by standard methods (24) and were stored as suspensions in water at
ambient temperature until used in the study. Prior to testing, each
isolate was subcultured at least twice to Sabouraud dextrose agar
(Remel, Lenexa, Kars.) to ensure optimal growth characteristics.
Antifungal agents.
Etest strips containing caspofungin
(MK-0991) were supplied by AB BIODISK (Solna, Sweden). Caspofungin was
obtained as a reagent-grade powder from Merck Research Laboratories.
Stock solutions were prepared in water and further diluted in RPMI 1640 medium buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid
(MOPS) buffer (Sigma, St. Louis, Mo.) and dispensed into 96-well
microdilution trays. Trays containing a 0.1-ml aliquot of appropriate
drug solution (twice the final concentration) in each well were
subjected to quality control (QC) testing and then sealed and stored at
Media.
Agar formulations used for the Etest were RPMI 1640 (American Biorganics, Buffalo, N.Y.) supplemented with 1.5% agar and
2% glucose (RPG) and buffered with MOPS, Casitone agar (CAS; Difco) and antibiotic medium 3 agar (AM3; BBL). The RPMI 1640 broth medium used for the microdilution testing was buffered with MOPS in accordance with the NCCLS M27-A method (12).
Antifungal susceptibility testing methods.
Broth
microdilution tests were performed as specified by NCCLS document M27-A
(12). A stock inoculum suspension of 1 × 106 to 5 × 106 cells per ml was
standardized spectrophotometrically at 530 nm to match the turbidity of
a 0.5 McFarland standard, diluted 1:1,000 with medium, and validated by
quantitative plate counts, to provide a test inoculum of 0.5 × 103 to 2.5 × 103 cells per ml. The
microdilution trays were incubated at 35°C and read after 48 h
of incubation. For caspofungin (MK-0991), the MIC end point was defined
as the lowest concentration of antifungal agent that completely
inhibited growth.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.12.4387-4389.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Evaluation of Etest Method for Determining Caspofungin (MK-0991)
Susceptibilities of 726 Clinical Isolates of Candida
Species
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
70°C until used in the study. The final concentrations of
caspofungin were 0.007 to 8 µg/ml.
QC. QC testing was performed as described by NCCLS document M27-A using C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 (12). QC determinations made on each day of testing were within the control limits for caspofungin as established by Barry et al. (2): C. krusei ATCC 6258, 0.25 to 1.0 µg/ml; C. parapsilosis ATCC 22019, 0.5 to 4.0 µg/ml.
Analysis of results. Etest MICs read at 48 h on the three media were compared to reference microdilution MICs read at 48 h. All 726 isolates were tested on RPG agar. A subset of 314 isolates were also tested by Etest on CAS and AM3 agar. Since the Etest scale has a continuous gradient of concentrations, the MICs in between twofold dilutions were raised to the next twofold level of the reference method for comparison (16, 17, 19, 20). Off-scale MICs at the upper limit were converted to the next higher concentration, and off-scale results at the lower limit were left unchanged. Discrepancies between MICs of no more than two dilutions were used to calculate the percent agreement.
| |
RESULTS AND DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
|
|---|
Table 1 summarizes the in vitro
susceptibilities of 726 Candida spp. isolates to caspofungin
as determined by the reference broth microdilution method. The
caspofungin MICs obtained were consistent with values reported
previously for the individual Candida species tested in RPMI
1640 medium (3, 11, 13, 22). Lower MICs of caspofungin
have been reported when isolates of Candida spp. were tested
in A3 broth (11). Thus, the MIC data shown in Table 1 may
underestimate the activity of caspofungin.
|
Table 2 summarizes the percentage of 48-h
caspofungin MICs obtained for all 726 isolates by the Etest on RPG agar
and for the 312 isolates tested on Casitone and AM3 agar that were
within two dilutions of the reference method result. Overall, the
percent agreement was 94% with results obtained for RPG agar. The
agreement between the Etest using RPG agar and microdilution MICs was
>90% for all species except C. tropicalis and C. parapsilosis. Of the 10 discrepancies observed with C. parapsilosis, 4 were corrected when Etest results obtained after a
24-h incubation were used. In general, however, the 24-h Etest results
yielded a lower percent agreement with the reference method than that
obtained with 48 h readings. The agreement between Etest and
microdilution MICs was poorer when either Casitone (82% agreement) or
AM3 (79% agreement) was used (Table 2); however, 
80% agreement was
achieved on both media with C. albicans, C. glabrata, C. krusei, and C. guilliermondii. In most instances (75%) when a discrepancy was observed between Etest
and the reference method, the Etest provided a lower MIC.
|
The results of this study provide the first documentation of the applicability of the Etest stable-agar-gradient method for determining the in vitro susceptibilities of Candida species to the glucan synthesis inhibitor caspofungin. Recently, Lozano-Chiu et al. (10) demonstrated the feasibility of agar-based methods for testing this agent when they reported a disk diffusion method using RPG agar for determining the susceptibilities of Candida spp. to caspofungin. These authors tested 94 isolates by both disk and reference broth microdilution methods and found that the results obtained in the disk test correlated well with those obtained by the broth microdilution method (10). Similar to our results, they found that when discrepancies between agar- and broth-based methods were observed, the agar-based disk method result was always more susceptible.
In the present study, we found that RPG provided optimal growth of all species tested and excellent agreement with the MICs obtained in the broth microdilution method (Table 2). As noted by Lozano-Chiu with the disk test (10), the inhibition ellipses were sharply defined and the MICs were easily determined with the Etest.
Neither Casitone agar nor AM3 agar performed particularly well in this study. In most instances, the MIC of caspofungin was underestimated by more than two dilutions when determined on these media relative to the broth MIC. Both media supported adequate growth of Candida spp., as reported previously (16, 17, 20, 23). It is notable that the antifungal activity of caspofungin (MK-0991) has been shown to be enhanced in AM3 broth (11). Thus, it is conceivable that better agreement between broth dilution and Etest MICs could be achieved if organisms were tested in AM3 broth as well as agar, but this was not done in the present study.
In summary, we have provided the first documentation of the ability of the Etest to generate caspofungin MIC data that are comparable to those obtained by the NCCLS broth microdilution method. It is now apparent that Etest using RPG may be used to test Candida, Cryptococcus, and other yeasts against polyenes, triazoles, and inhibitors of glucan synthesis (9, 16, 17, 20, 23). This provides great flexibility to laboratories that may want to test only one or two agents yet provide quantitative MIC data that are comparable to that generated by the NCCLS reference broth dilution method. The flexibility of the Etest technology will stimulate additional unique applications that may add to our understanding of the in vitro interactions between fungi and antifungal agents.
| |
ACKNOWLEDGMENTS |
|---|
The excellent secretarial support of K. Meyer is greatly appreciated.
This study was supported in part by Merck Research Laboratories and by AB BIODISK.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 384-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu.
Present address: Jones Group/JMI Laboratories, 345 Beaver Kreek
Centre, Suite A, North Liberty, IA 52317.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
|
|---|
| 1. | Barry, A. L., and S. D. Brown. 1996. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J. Clin. Microbiol. 34:2154-2157[Abstract]. |
| 2. |
Barry, A. L.,
M. A. Pfaller,
S. D. Brown,
A. Espinel-Ingroff,
M. A. Ghannoum,
C. Knapp,
R. P. Rennie,
J. H. Rex, and M. G. Rinaldi.
2000.
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.
J. Clin. Microbiol.
38:3457-3459 |
| 3. | Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, and P. M. Scott. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332[Abstract]. |
| 4. |
Chen, S. C. A.,
M. L. O'Donnell,
S. Gordon, and G. L. Gilbert.
1996.
Antifungal susceptibility testing using the Etest: comparison with the broth macrodilution technique.
J. Antimicrob. Chemother.
37:265-273 |
| 5. |
Colombo, A. L.,
F. Barchiesi,
D. A. McGough,
A. W. Fothergill, and M. G. Rinaldi.
1995.
Evaluation of the Etest system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole.
J. Antimicrob. Chemother.
36:93-100 |
| 6. | Espinel-Ingroff, A., M. Pfaller, M. E. Erwin, and R. N. Jones. 1996. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J. Clin. Microbiol. 34:848-852[Abstract]. |
| 7. | Espinel-Ingroff, A., T. White, and M. A. Pfaller. 1999. Antifungal agents and susceptibility tests, p. 1640-1652. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C. |
| 8. | Jorgensen, J. H., J. D. Turnidge, and J. A. Washington. 1999. Antibacterial susceptibility tests: dilution and disk diffusion methods, p. 1526-1543. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of Clinical Microbiology, 7th ed. ASM Press, Washington, D.C. |
| 9. |
Lozano-Chiu, M.,
V. L. Paetznick,
M. A. Ghannoum, and J. H. Rex.
1998.
Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performance of three different media assessed by using Etest and National Committee for Clinical Laboratory Standards M27-A methodologies.
J. Clin. Microbiol.
36:2817-2822 |
| 10. |
Lozano-Chiu, M.,
P. W. Nelson,
V. L. Paetznick, and J. H. Rex.
1999.
Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991.
J. Clin. Microbiol.
37:1625-1627 |
| 11. | Marco, F., M. A. Pfaller, S. A. Messer, and R. N. Jones. 1998. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 32:33-37[CrossRef][Medline]. |
| 12. | National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 13. | Nelson, P. W., M. Lozano-Chiu, and J. H. Rex. 1997. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J. Med. Vet. Mycol. 35:285-287[Medline]. |
| 14. | Pfaller, M. A. 2000. Antifungal susceptibility testing: progress and future developments. Braz. J. Infect. Dis. 4:55-60[Medline]. |
| 15. | Pfaller, M. A., J. H. Rex, and M. G. Rinaldi. 1997. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin. Infect. Dis. 24:776-784[Medline]. |
| 16. |
Pfaller, M. A.,
S. A. Messer,
A. Karlsson, and A. Bolmstrom.
1998.
Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media.
J. Clin. Microbiol.
36:2586-2589 |
| 17. | Pfaller, M. A., S. A. Messer, and A. Bolmstrom. 1998. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn. Microbiol. Infect. Dis. 32:223-227[CrossRef][Medline]. |
| 18. |
Pfaller, M. A.,
S. A. Messer,
R. J. Hollis,
R. N. Jones,
G. V. Doern,
M. E. Brandt, and R. A. Hajjeh.
1998.
In vitro susceptibilities of Candida blood stream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Antimicrob. Agents Chemother.
42:3242-3244 |
| 19. |
Pfaller, M. A.,
S. A. Messer,
K. Mills, and A. Bolmstrom.
2000.
In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs.
J. Clin. Microbiol.
38:3359-3361 |
| 20. |
Pfaller, M. A.,
S. A. Messer,
A. Houston,
K. Mills,
A. Bolmstrom, and R. N. Jones.
2000.
Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.
J. Clin. Microbiol.
38:3715-3717 |
| 21. |
Szekely, A.,
E. M. Johnson, and D. W. Warnock.
1999.
Comparison of Etest and broth microdilution methods for antifungal drug susceptibility testing of moulds.
J. Clin. Microbiol.
37:1480-1483 |
| 22. | Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614[Abstract]. |
| 23. | Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522[Abstract]. |
| 24. | Warren, N. G., and K. C. Hazen. 1999. Candida, Cryptococcus, and other yeasts of medical importance, p. 1184-1199. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C. |
Journal of Clinical Microbiology, December 2001, p. 4387-4389, Vol. 39, No. 12
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.12.4387-4389.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Arendrup, M. C., Garcia-Effron, G., Buzina, W., Mortensen, K. L., Reiter, N., Lundin, C., Jensen, H. E., Lass-Florl, C., Perlin, D. S., Bruun, B.
(2009). Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing. Antimicrob. Agents Chemother.
53: 1185-1193
[Abstract] [Full Text] -
Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., Dannaoui, E.
(2008). Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother.
52: 3092-3098
[Abstract] [Full Text] -
Desnos-Ollivier, M., Dromer, F., Dannaoui, E.
(2008). Detection of Caspofungin Resistance in Candida spp. by Etest. J. Clin. Microbiol.
46: 2389-2392
[Abstract] [Full Text] -
Johnson, E. M.
(2008). Issues in antifungal susceptibility testing. J Antimicrob Chemother
61: i13-i18
[Abstract] [Full Text] -
Girmenia, C., Pizzarelli, G., Cristini, F., Barchiesi, F., Spreghini, E., Scalise, G., Martino, P.
(2006). Candida guilliermondii Fungemia in Patients with Hematologic Malignancies.. J. Clin. Microbiol.
44: 2458-2464
[Abstract] [Full Text] -
Odds, F. C., Motyl, M., Andrade, R., Bille, J., Canton, E., Cuenca-Estrella, M., Davidson, A., Durussel, C., Ellis, D., Foraker, E., Fothergill, A. W., Ghannoum, M. A., Giacobbe, R. A., Gobernado, M., Handke, R., Laverdiere, M., Lee-Yang, W., Merz, W. G., Ostrosky-Zeichner, L., Peman, J., Perea, S., Perfect, J. R., Pfaller, M. A., Proia, L., Rex, J. H., Rinaldi, M. G., Rodriguez-Tudela, J.-L., Schell, W. A., Shields, C., Sutton, D. A., Verweij, P. E., Warnock, D. W.
(2004). Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. J. Clin. Microbiol.
42: 3475-3482
[Abstract] [Full Text] -
Pujol, C., Messer, S. A., Pfaller, M., Soll, D. R.
(2003). Drug Resistance Is Not Directly Affected by Mating Type Locus Zygosity in Candida albicans. Antimicrob. Agents Chemother.
47: 1207-1212
[Abstract] [Full Text] -
Maxwell, M. J., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Diekema, D. J., Pfaller, M. A.
(2003). Evaluation of Etest Method for Determining Fluconazole and Voriconazole MICs for 279 Clinical Isolates of Candida Species Infrequently Isolated from Blood. J. Clin. Microbiol.
41: 1087-1090
[Abstract] [Full Text] -
Pfaller, J. B., Messer, S. A., Hollis, R. J., Diekema, D. J., Pfaller, M. A.
(2003). In Vitro Susceptibility Testing of Aspergillus spp.: Comparison of Etest and Reference Microdilution Methods for Determining Voriconazole and Itraconazole MICs. J. Clin. Microbiol.
41: 1126-1129
[Abstract] [Full Text] -
Espinel-Ingroff, A.
(2003). Evaluation of Broth Microdilution Testing Parameters and Agar Diffusion Etest Procedure for Testing Susceptibilities of Aspergillus spp. to Caspofungin Acetate (MK-0991). J. Clin. Microbiol.
41: 403-409
[Abstract] [Full Text] -
Chryssanthou, E., Cuenca-Estrella, M.
(2002). Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing Proposed Standard and the E-Test with the NCCLS Broth Microdilution Method for Voriconazole and Caspofungin Susceptibility Testing of Yeast Species. J. Clin. Microbiol.
40: 3841-3844
[Abstract] [Full Text] -
Kuhn, D. M., George, T., Chandra, J., Mukherjee, P. K., Ghannoum, M. A.
(2002). Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins. Antimicrob. Agents Chemother.
46: 1773-1780
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»